Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
The Supreme Court unanimously ruled that Amarin Pharma could not sue generic drugmaker Hikma for patent infringement based on vague product descriptions, because those statements did not amount to actively encouraging doctors to prescribe the drug for a patented use Hikma deliberately left off its label.
The decision makes it harder for brand-name drugmakers to use patent suits to block generic competition when the generic uses an abbreviated 'skinny label,' clarifying that only deliberate, affirmative encouragement of infringing use — not routine commercial descriptions — can trigger liability.
“We decline to put generic manufacturers between a rock and a hard place by turning adherence to the law and industry standards into building blocks for illegal conduct.”
The Court explaining why following federal labeling rules and standard industry practice cannot be used as evidence of patent inducement.
How it got here: The federal trial court dismissed Amarin's suit; the Federal Circuit reversed; Hikma asked the Supreme Court to step in and the Court agreed to hear the case.
The Case in Depth
What happened
Amarin Pharma makes Vascepa, an omega-3 fatty acid drug first approved for a rare condition (severely high triglycerides) and later patented for reducing cardiovascular risk in a broader patient group already taking statins. Hikma, a generic manufacturer, received FDA approval with a "skinny label" — an abbreviated label that carved out the patented cardiovascular use and covered only the older, unpatented use. Amarin sued, arguing that Hikma's label, website, and investor press releases together nudged doctors into prescribing the drug for the patented use.
The question before the Court
Can a generic drug company be held liable for inducing patent infringement based on routine product descriptions — like calling its drug a "generic equivalent" — even when its official label deliberately leaves out the patented use?
The Court's answer
No — a generic drug company does not commit patent infringement simply because its routine product descriptions might lead some doctors to prescribe the drug for a patented use the company deliberately left off its label. The law requires affirmative, purposeful steps to encourage infringing use — not just statements that could be read that way by someone.
The Court found that Hikma's statements either had obvious lawful explanations (federal law requires generic labels to mirror brand-name labels, and calling a drug the "generic equivalent" is standard industry practice) or were too vague and indirect to count as active encouragement. Warnings in patient leaflets, broad therapeutic-category descriptions on a website, an equivalency rating, and investor-facing sales figures do not add up to the deliberate promotion of infringement the statute requires.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Generic drugmakers relying on skinny labels can now describe their products as brand equivalents and comply with standard labeling rules without those acts becoming the foundation of a patent lawsuit. Brand-name companies hoping to slow generic competition through induced-infringement claims will need far more direct evidence that the generic maker deliberately pushed doctors toward the patented use.
What changes now
The case is sent back to the lower courts, but Amarin's complaint cannot survive as written. To pursue an induced-infringement claim, Amarin would need substantially more specific evidence of deliberate encouragement — vague descriptions and regulatory-compliance statements will not suffice. The ruling applies broadly across the generic drug industry, giving manufacturers who use skinny labels clearer protection against patent suits based on routine commercial communications.
What this does not decide
The Court did not hold that a generic maker using a skinny label can never be liable for inducing patent infringement — only that Amarin's specific allegations fell short at the pleading stage. The decision also does not resolve broader policy debates about whether the skinny-label system adequately protects brand-name patent rights.
Concurrences and dissents
How the Justices voted
Majority (1). Justice Jackson (author).
How the Court got there
The legal reasoning, step by step
- Federal patent law makes it illegal to 'actively induce' someone to infringe a patent (35 U.S.C. §271(b)). Courts have identified three required elements: a third party must actually commit infringement, the inducer must know the conduct infringes, and — the element at issue here — the inducer must take 'active steps' to encourage infringement. Only the third element was disputed.
- Drawing on its 2005 ruling in *Grokster* (a copyright case about file-sharing software), the Court defined 'active steps' as affirmative, purposeful conduct designed to bring about infringement — like newsletters promoting illegal file-sharing or ads urging users to adopt tools built for piracy. Statements that merely *could* be read as encouragement are not enough; the conduct must be designed to stimulate others to infringe.
- The standard for surviving a motion to dismiss requires allegations that are 'plausible' — a court must be able to draw a reasonable inference of wrongdoing and rule out obvious innocent explanations. A mere possibility of wrongdoing is insufficient under the Court's prior pleading standards from *Twombly* and *Iqbal*.
- Hikma's label retained clinical study information and omitted the patented cardiovascular 'limitation of use' — but that is because federal law requires generic labels to mirror the brand-name label. Describing the drug as the 'generic equivalent' of Vascepa is standard industry practice explicitly recognized in prior case law. Compliance with the law and industry norms cannot be recast as building blocks for inducement liability.
- Omissions — such as not mentioning that Hikma's label was limited to the older, less-known use — cannot by themselves constitute the affirmative action the law requires. The Court emphasized that basing liability on inaction would expose ordinary merchants to patent liability for any foreseeable misuse of their products, however distant their connection to the wrongdoing.
- The remaining statements — a broad therapeutic-category description on Hikma's website, an FDA equivalency rating, and investor-targeted press-release sales figures — were too vague and indirect to plausibly reflect a design to promote infringement, especially since Hikma's own website stated its generic covered fewer uses than Vascepa. Requiring a long, speculative chain of events for a medical provider to read encouragement into these statements is precisely what the plausibility standard forbids.
Doctrinal impact
Cases affected by this decision
Reaffirms Metro-Goldwyn-Mayer Studios Inc. v. Grokster, Ltd. (545 U.S. 913)
Court reaffirms that inducement requires purposeful, affirmative steps to promote infringement, not mere knowledge or passive conduct.